Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Jean‐Marie Michot, Camille Bigenwald, Stéphane Champiat et al. · European Journal of Cancer · 2016
Cited by 2,121 works. doi:10.1016/j.ejca.2015.11.016
Authors
- Jean‐Marie Michot
- Camille Bigenwald
- Stéphane Champiat
- Michael Collins
- Franck Carbonnel
- Sophie C. Postel-Vinay
- Amandine Berdelou
- Rastislav Bahleda
- Antoine Hollebecque
- Christophe Massard
- Alina Cristina Fuerea
- Vincent Ribrag
- Anas Gazzah
- Jean‐Pierre Armand
- Nadia Amellal
- Eric Angevin
- Nicolas Noël
- C. Boutros
- Christine Mateus
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus